Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 1.19
RELV's Cash to Debt is ranked higher than
61% of the 917 Companies
in the Global Biotechnology industry.

( Industry Median: 20.79 vs. RELV: 1.19 )
RELV' s 10-Year Cash to Debt Range
Min: 0.16   Max: No Debt
Current: 1.19

Equity to Asset 0.59
RELV's Equity to Asset is ranked higher than
68% of the 766 Companies
in the Global Biotechnology industry.

( Industry Median: 0.65 vs. RELV: 0.59 )
RELV' s 10-Year Equity to Asset Range
Min: 0.28   Max: 0.74
Current: 0.59

0.28
0.74
Interest Coverage 18.32
RELV's Interest Coverage is ranked higher than
56% of the 429 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. RELV: 18.32 )
RELV' s 10-Year Interest Coverage Range
Min: 1.95   Max: 7295
Current: 18.32

1.95
7295
F-Score: 3
Z-Score: 3.03
M-Score: -1.94
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) 1.03
RELV's Operating margin (%) is ranked higher than
81% of the 825 Companies
in the Global Biotechnology industry.

( Industry Median: -65.07 vs. RELV: 1.03 )
RELV' s 10-Year Operating margin (%) Range
Min: -2.5   Max: 10.98
Current: 1.03

-2.5
10.98
Net-margin (%) 0.57
RELV's Net-margin (%) is ranked higher than
81% of the 825 Companies
in the Global Biotechnology industry.

( Industry Median: -70.66 vs. RELV: 0.57 )
RELV' s 10-Year Net-margin (%) Range
Min: -2.02   Max: 6.72
Current: 0.57

-2.02
6.72
ROE (%) 2.26
RELV's ROE (%) is ranked higher than
83% of the 862 Companies
in the Global Biotechnology industry.

( Industry Median: -21.70 vs. RELV: 2.26 )
RELV' s 10-Year ROE (%) Range
Min: -20.59   Max: 59.86
Current: 2.26

-20.59
59.86
ROA (%) 1.33
RELV's ROA (%) is ranked higher than
84% of the 920 Companies
in the Global Biotechnology industry.

( Industry Median: -18.92 vs. RELV: 1.33 )
RELV' s 10-Year ROA (%) Range
Min: -6.73   Max: 28.95
Current: 1.33

-6.73
28.95
ROC (Joel Greenblatt) (%) 8.79
RELV's ROC (Joel Greenblatt) (%) is ranked higher than
87% of the 905 Companies
in the Global Biotechnology industry.

( Industry Median: -215.73 vs. RELV: 8.79 )
RELV' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -14.58   Max: 128.29
Current: 8.79

-14.58
128.29
Revenue Growth (%) -5.80
RELV's Revenue Growth (%) is ranked higher than
72% of the 648 Companies
in the Global Biotechnology industry.

( Industry Median: -0.90 vs. RELV: -5.80 )
RELV' s 10-Year Revenue Growth (%) Range
Min: -8.4   Max: 21.7
Current: -5.8

-8.4
21.7
EBITDA Growth (%) -18.40
RELV's EBITDA Growth (%) is ranked higher than
67% of the 626 Companies
in the Global Biotechnology industry.

( Industry Median: -8.10 vs. RELV: -18.40 )
RELV' s 10-Year EBITDA Growth (%) Range
Min: -51   Max: 133.6
Current: -18.4

-51
133.6
EPS Growth (%) -24.60
RELV's EPS Growth (%) is ranked higher than
67% of the 645 Companies
in the Global Biotechnology industry.

( Industry Median: -10.20 vs. RELV: -24.60 )
RELV' s 10-Year EPS Growth (%) Range
Min: -43.3   Max: 149.3
Current: -24.6

-43.3
149.3
» RELV's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

RELV Guru Trades in Q3 2013

Jim Simons 333,700 sh (+1.86%)
» More
Q4 2013

RELV Guru Trades in Q4 2013

Jim Simons 329,000 sh (-1.41%)
» More
Q1 2014

RELV Guru Trades in Q1 2014

Jim Simons 326,100 sh (-0.88%)
» More
Q2 2014

RELV Guru Trades in Q2 2014

Jim Simons 326,400 sh (+0.09%)
» More
» Details

Insider Trades

Latest Guru Trades with RELV

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 43.10
RELV's P/E(ttm) is ranked higher than
91% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. RELV: 43.10 )
RELV' s 10-Year P/E(ttm) Range
Min: 11.11   Max: 79.17
Current: 43.1

11.11
79.17
P/B 1.00
RELV's P/B is ranked higher than
98% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 6.41 vs. RELV: 1.00 )
RELV' s 10-Year P/B Range
Min: 0.94   Max: 21.08
Current: 1

0.94
21.08
P/S 0.30
RELV's P/S is ranked higher than
100% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 20.67 vs. RELV: 0.30 )
RELV' s 10-Year P/S Range
Min: 0.2   Max: 2.43
Current: 0.3

0.2
2.43
PFCF 62.50
RELV's PFCF is ranked higher than
92% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. RELV: 62.50 )
RELV' s 10-Year PFCF Range
Min: 6.15   Max: 280
Current: 62.5

6.15
280
EV-to-EBIT 22.68
RELV's EV-to-EBIT is ranked higher than
93% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. RELV: 22.68 )
RELV' s 10-Year EV-to-EBIT Range
Min: 5.5   Max: 42.6
Current: 22.68

5.5
42.6
Shiller P/E 10.90
RELV's Shiller P/E is ranked higher than
99% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. RELV: 10.90 )
RELV' s 10-Year Shiller P/E Range
Min: 4.62   Max: 155
Current: 10.9

4.62
155
Current Ratio 1.73
RELV's Current Ratio is ranked higher than
57% of the 707 Companies
in the Global Biotechnology industry.

( Industry Median: 4.31 vs. RELV: 1.73 )
RELV' s 10-Year Current Ratio Range
Min: 0.99   Max: 2.88
Current: 1.73

0.99
2.88
Quick Ratio 0.96
RELV's Quick Ratio is ranked higher than
53% of the 707 Companies
in the Global Biotechnology industry.

( Industry Median: 3.96 vs. RELV: 0.96 )
RELV' s 10-Year Quick Ratio Range
Min: 0.4   Max: 2.33
Current: 0.96

0.4
2.33

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 0.80
RELV's Dividend Yield is ranked lower than
60% of the 174 Companies
in the Global Biotechnology industry.

( Industry Median: 1.17 vs. RELV: 0.80 )
RELV' s 10-Year Dividend Yield Range
Min: 0.35   Max: 3.33
Current: 0.8

0.35
3.33
Dividend Payout 0.36
RELV's Dividend Payout is ranked higher than
94% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. RELV: 0.36 )
RELV' s 10-Year Dividend Payout Range
Min: 0.08   Max: 3
Current: 0.36

0.08
3
Dividend growth (3y) -9.10
RELV's Dividend growth (3y) is ranked higher than
70% of the 79 Companies
in the Global Biotechnology industry.

( Industry Median: 10.90 vs. RELV: -9.10 )
RELV' s 10-Year Dividend growth (3y) Range
Min: 0   Max: 41.9
Current: -9.1

0
41.9
Yield on cost (5-Year) 0.30
RELV's Yield on cost (5-Year) is ranked lower than
85% of the 180 Companies
in the Global Biotechnology industry.

( Industry Median: 1.19 vs. RELV: 0.30 )
RELV' s 10-Year Yield on cost (5-Year) Range
Min: 0.13   Max: 1.23
Current: 0.3

0.13
1.23
Share Buyback Rate -1.20
RELV's Share Buyback Rate is ranked higher than
91% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -10.10 vs. RELV: -1.20 )
RELV' s 10-Year Share Buyback Rate Range
Min: 8.8   Max: -10.1
Current: -1.2

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 1.30
RELV's Price/Tangible Book is ranked higher than
97% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 9.62 vs. RELV: 1.30 )
RELV' s 10-Year Price/Tangible Book Range
Min: 1.15   Max: 16.48
Current: 1.3

1.15
16.48
Price/DCF (Projected) 0.50
RELV's Price/DCF (Projected) is ranked higher than
100% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. RELV: 0.50 )
RELV' s 10-Year Price/DCF (Projected) Range
Min: 0.31   Max: 54.6
Current: 0.5

0.31
54.6
Price/Median PS Value 0.40
RELV's Price/Median PS Value is ranked higher than
97% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 1.97 vs. RELV: 0.40 )
RELV' s 10-Year Price/Median PS Value Range
Min: 0.21   Max: 3.11
Current: 0.4

0.21
3.11
Price/Graham Number 1.60
RELV's Price/Graham Number is ranked higher than
97% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. RELV: 1.60 )
RELV' s 10-Year Price/Graham Number Range
Min: 0.79   Max: 5.17
Current: 1.6

0.79
5.17
Earnings Yield (Greenblatt) 4.20
RELV's Earnings Yield (Greenblatt) is ranked higher than
75% of the 469 Companies
in the Global Biotechnology industry.

( Industry Median: 5.00 vs. RELV: 4.20 )
RELV' s 10-Year Earnings Yield (Greenblatt) Range
Min: 2.3   Max: 18.1
Current: 4.2

2.3
18.1
Forward Rate of Return (Yacktman) -7.89
RELV's Forward Rate of Return (Yacktman) is ranked higher than
76% of the 757 Companies
in the Global Biotechnology industry.

( Industry Median: -10.00 vs. RELV: -7.89 )
RELV' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -13.5   Max: 43.8
Current: -7.89

-13.5
43.8

Business Description

Industry: Biotechnology » Biotechnology
Compare:NONOF, AMGN, GILD, BIIB, CELG » details
Reliv' International, Inc., is a Delaware corporation. The Company is a developer, manufacturer and marketer of a proprietary line of nutritional supplements addressing basic nutrition, specific wellness needs, weight management and sports nutrition. All but one of its science-based supplements are packaged in powdered form and, when mixed with water, juice or other liquid and consumed, provide an effective means of delivering nutrients to the body. It also offers a ready-to-drink product and a line of skin care and food products. It sells its products through an international network marketing system using independent distributors. It currently offers 17 nutritional supplements. In addition, it markets a line of 7 skin care and food products under its Relivables brand. Its core line of nutritional supplements include: Reliv Classic and Reliv NOW - two basic nutritional supplements containing a full and balanced blend of vitamins, minerals, proteins and herbs; Innergize! - an isotonic sports supplement in three flavors; and FibRestore - a high-fiber and antioxidant supplement. It has 13 other nutritional supplements that complement these four core products. It manufactures all of its powdered nutritional supplements at its facility in Chesterfield, Missouri. Four basic nutrition supplements provide consumers with a broad spectrum of essential nutrients. Reliv Classic is a nutritional supplement containing a variety of vitamins and minerals, soy and other protein sources and various herbs. It is a vegetarian product that contains no animal compounds, artificial preservatives, artificial flavors or added simple sugars. Reliv NOW is a nutritional supplement containing a variety of vitamins and minerals, soy and other protein sources and various herbs. NOW for Kids is a product designed to provide a balanced nutritional supplement for a child's diet and contains a variety of vitamins and minerals. Reliv Delight is a powdered nutritional supplement marketed as a milk replacement. Reliv Delight is available in Mexico and the United States. Its line of six specific wellness supplements contains specific compounds that target certain conditions and promote health. It four weight management supplements combine advanced weight loss promoting complexes with scientifically balanced nutrition and health enhancing soy protein and two sports nutrition supplements contain a balance of nutrients scientifically designed to improve athletic performance and endurance, as well as muscle recovery and repair. Its competitors include both network marketing companies such as Alticor Inc., Avon Products Inc., Herbalife Ltd., Mary Kay Inc., Melaleuca, Inc., Mannatech, Inc., Nature's Sunshine Products Inc., NuSkin Enterprises Inc. and USANA Health Sciences Inc., as well as specialty and mass retail establishments.
» More Articles for RELV

Headlines

Articles On GuruFocus.com
52 wk low, 30% owned Mar 01 2013 
1.13 Feb 12 2012 
18 Stocks Meeting the Goal of Higher Dividends May 09 2011 
Guru Stocks Raising Dividends: KNL, DTE, UNP, RELV, HWCC May 09 2011 
Reliv International Masking Poor Results Apr 23 2010 
Reliv International Schedules Fourth Quarter and Year-End 2008 Earnings Release and Conference Call Feb 02 2009 

More From Other Websites
RELIV INTERNATIONAL INC Financials Aug 22 2014
RELIV INTERNATIONAL INC Files SEC form 10-Q, Quarterly Report Aug 13 2014
RELIV INTERNATIONAL INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Jul 31 2014
Reliv International Reports Second-Quarter Financial Results Jul 31 2014
3 Stocks Pushing The Health Care Sector Lower Jul 24 2014
3 Drugs Stocks Moving The Industry Upward Jul 22 2014
3 Stocks Improving Performance Of The Health Care Sector Jul 22 2014
3 Stocks Pushing The Health Care Sector Lower Jul 16 2014
Reliv Unveils International Conference Agenda Jul 08 2014
RELIV INTERNATIONAL INC Files SEC form 10-Q, Quarterly Report May 14 2014
RELIV INTERNATIONAL INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Apr 30 2014
RELIV INTERNATIONAL INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial... Apr 03 2014
RELIV INTERNATIONAL INC Files SEC form 10-K, Annual Report Mar 25 2014
RELIV INTERNATIONAL INC Files SEC form 8-K, Creation of a Direct Financial Obligation or an... Mar 06 2014
RELIV INTERNATIONAL INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Mar 05 2014
Is The Federal Trade Commission Stating Its Current Enforcement Posture On MLMs? Jan 02 2014
Reliv Kalogris Foundation Contributes $600K in Nutritional Products and Cash to Typhoon Haiyan... Dec 17 2013
LunaRich, Nutritional Epigenetics Provide Business Boost for Reliv Dec 17 2013
RELIV INTERNATIONAL INC Files SEC form 8-K, Change in Directors or Principal Officers Nov 18 2013
RELIV INTERNATIONAL INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Oct 31 2013

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK